Quantification of Muscle Contraction In Vitro and In Vivo Using MUSCLEMOTION Software: From Stem Cell‐Derived Cardiomyocytes to Zebrafish and Human Hearts

Quantification of contraction is essential to the study of cardiac diseases, injury, and responses to drugs. While there are many techniques to assess contractility, most rely on costly, dedicated hardware and advanced informatics, and can only be used in specific experimental models. We have developed an automated open‐source software tool (MUSCLEMOTION) for use with standard imaging equipment, to assess contractility in vitro and in vivo and quantify responses to drugs and diseases. We describe high‐speed and disturbance‐free acquisition of images from either electrically paced or non‐paced human pluripotent stem cell‐derived cardiomyocytes, isolated adult cardiomyocytes, zebrafish hearts, and human echocardiograms. Recordings are then used as input for automated batch analysis by the MUSCLEMOTION software tool configured with specific settings and parameters tailored to the recording technique. Details on accuracy, interpretation, and troubleshooting are discussed. Acquisition duration depends on the experimental setup and aim, but quantification of drug or disease responses in an in vitro muscle model can typically be completed within a few hours. © 2018 by John Wiley & Sons, Inc.

[1]  Godfrey L. Smith,et al.  MUSCLEMOTION , 2017, Circulation research.

[2]  Adriaan P IJzerman,et al.  A new hERG allosteric modulator rescues genetic and drug‐induced long‐QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells , 2016, EMBO molecular medicine.

[3]  Thomas Eschenhagen,et al.  Differentiation of cardiomyocytes and generation of human engineered heart tissue , 2017, Nature Protocols.

[4]  Christine L. Mummery,et al.  Concise Review: Measuring Physiological Responses of Human Pluripotent Stem Cell Derived Cardiomyocytes to Drugs and Disease , 2016, Stem cells.

[5]  R. Pölönen,et al.  Mutation-specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of iPSC derived cardiomyocytes , 2019, Molecular Biology Reports.

[6]  Richard P Davis,et al.  Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes Under Defined Conditions. , 2016, Methods in molecular biology.

[7]  Kelly Rae Chi Revolution dawning in cardiotoxicity testing , 2013, Nature Reviews Drug Discovery.

[8]  Marie C. Phelan Techniques for Mammalian Cell Tissue Culture , 2001, Current protocols in protein science.

[9]  P. Schwartz,et al.  Long QT Syndrome Modelling with Cardiomyocytes Derived from Human-induced Pluripotent Stem Cells , 2018, Arrhythmia & electrophysiology review.

[10]  D. Beis,et al.  On Zebrafish Disease Models and Matters of the Heart , 2019, Biomedicines.

[11]  P. Burridge,et al.  Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells , 2015, Current protocols in human genetics.

[12]  E. Stanley,et al.  A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies , 2008, Nature Protocols.